We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Immatics Nv
2 own
3 watching
Current Price
$7.85
$0.17
(2.21%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
920.82M
52-Week High
13.77000
52-Week Low
7.46000
Average Volume
0.41M
Dividend Yield
--
P/E Ratio
--
Market Capitalization920.82M52-Week High13.7700052-Week Low7.46000Average Volume0.41MDividend Yield--P/E Ratio--What does the Immatics Nv do?
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company s TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Read More
News & Events about Immatics Nv.
Ticker Report
1 year ago
Immatics (NASDAQ:IMTX Get Rating) and Tenaya Therapeutics (NASDAQ:TNYA Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, ...
Ticker Report
2years ago
Surrozen (NASDAQ:SRZN Get Rating) and Immatics (NASDAQ:IMTX Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, ...
Globe Newswire
2years ago
Houston, Texas and Tuebingen, Germany, October 10, 2022 Immatics N.V. (NASDAQ: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today that it has agreed to sell, by way of an underwritten ...
Globe Newswire
2years ago
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expressionUpdate covers data from 27 ...
Globe Newswire
2years ago
TCER IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-associated toxicities as part of overall favorable in vitro ...
Frequently Asked Questions
Frequently Asked Questions
What is Immatics Nv share price today?
Can Indians buy Immatics Nv shares?
How can I buy Immatics Nv shares from India?
Can Fractional shares of Immatics Nv be purchased?
What are the documents required to start investing in Immatics Nv stocks?
What is today’s traded volume of Immatics Nv?
What is today’s market capitalisation of Immatics Nv?
What is the 52-Week High and Low Range of Immatics Nv?
What percentage is Immatics Nv down from its 52-Week High?
What percentage is Immatics Nv up from its 52-Week Low?
Current Price
$7.85
$0.17
(2.21%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.